• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Pfizer Q2 net dips to Rs 111 cr

expressbpdNovember 14, 2017

Tag: Pfizer , dips , Rs

Pfizer’s offer for the San Francisco, California-based Medivation goes far beyond the company’s market value of $11.1 billion. Medivation shares closed at $67.16 in Friday trading (Reuters)

Standalone revenue from operations rose to Rs 571.11 crore

Pfizer reported a 12 per cent dip in standalone net profit to Rs 111.15 crore for the quarter ended September 30, 2017. The company had posted a net profit of Rs 126.33 crore for the corresponding period of the previous fiscal, Pfizer said in a filing to BSE.

Standalone revenue from operations rose to Rs 571.11 crore as against Rs 557.66 crore for the same period year ago.

Previous:Life Science Giant PPD Cuts an Undisclosed Number of Jobs

Next:Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Pfizer Q2 net dips to Rs 111 cr | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

BALLOON FILLER REGULATORS

BALLOON FILLER REGULATORS
Ursodeoxycholic acid

Ursodeoxycholic acid
AUTOMATIC LINE FOR FILLING AND CAPPING VIALS WITH STERILE POWDERS, SGFJ SERIES

AUTOMATIC LINE FOR FILLING AND CAPPING VIALS WITH STERILE POWDERS, SGFJ SERIES
Labconco FreeZone 4.5 Liter Benchtop Freeze Dryers

Labconco FreeZone 4.5 Liter Benchtop Freeze Dryers
first intermediate of moxifloxacin 

first intermediate of moxifloxacin 
Pipettors

Pipettors
F0.4 Digit-display Disperrsion Machine

F0.4 Digit-display Disperrsion Machine
Polyethersulphone (PES) Cartridge Filter

Polyethersulphone (PES) Cartridge Filter
Lactose ≥99.0% Food Additive supplier Sweeteners made in china

Lactose ≥99.0% Food Additive supplier Sweeteners made in china
Robotic Mass Comparators

Robotic Mass Comparators

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service